U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873229) titled 'DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine' on Sept. 16.
Brief Summary: This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK) of metformin (a MATE1/2-K probe substrate), midazolam (a CYP3A4 probe substrate), and caffeine (a CYP1A2 probe substrate).
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Steatohepatitis, Nonalcoholic
Osteo Arthritis
Intervention:
DRUG: ECC0509
ECC0509 will be administered orally.
DRUG: Metfor...